NCT01180790 - Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants | Biotech Hunter

Enrollment

122

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

April 30, 2013

Conditions

Hepatitis C

Interventions

DRUG

ACH-0141625 (Sovaprevir)

200 mg oral capsule once daily

DRUG

ACH-0141625 (Sovaprevir)

400 mg oral capsule once daily

DRUG

ACH-0141625 (Sovaprevir)

800 mg oral capsule once daily

DRUG

Placebo

Powder in capsule once daily

DRUG

Pegylated Interferon alpha-2a

180 micrograms (ug) once a week by subcutaneous injection

DRUG

Ribavirin

400 mg or 600 mg (morning \[AM\]) and 600 mg (evening \[PM\]) capsules taken orally twice daily

Trial Locations (18)

2650

Clinical Trial Site, Edegem

7100

Clinical Trial Site, Haine-Saint-Paul

9000

Clinical Trial Site, Ghent

10065

Clinical Trial Site, New York

19141

Clinical Trial Site, Philadelphia

23502

Clinical Trial Site, Norfolk

23602

Clinical Trial Site, Newport News

32803

Clinical Trial Site, Orlando

34209

Clinical Trial Site, Bradenton

60611

Clinical Trial Site, Chicago

63104

Clinical Trial Site, St Louis

66211

Clinical Trial Site, Overland Park

76012

Clinical Trial Site, Arlington

78215

Clinical Trial Site, San Antonio

89106

Clinical Trial Site, Las Vegas

90036

Clinical Trial Site, Los Angeles

90048

Clinical Trial Site, Los Angeles

94115

Clinical Trial Site, San Francisco